|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Vertebroplasty:only smal cement volumes are required to normalize stress distributions on the vertebral bodies显示文摘 | Luo J Daines L Charalambous A | | 0，，1976： | 1 |
| 2 | Heart valve engineering:decel ularized aortic homograft seeded with human cardiac stromal cel s显示文摘 | Dainese L Guarino A Burba I | | 0，，01： | 1 |
| 3 | Preoperative assessment of the radial artery for coronary artery bypass grafting: is the clinical Alien test adequate? 显示文摘 | Agrifoglio M Dainese L Pasotti S | 2005 | Ann Thorac Surg2005，79，： | 1 |
| 4 | Reduction ascending aortoplasty: midterm follow-up and predictors of redilatation 显示文摘 | Polvani G Barili F Dainese L | 2006 | Ann Thorac Surg2006，82，2： | 1 |
| 5 | Vertebroplasty:only smal cement volumes are required to normalize stress distributions on the vertebral bodies显示文摘 | Luo J Daines L Charalambous A | | 0，，04： | 1 |
| 6 | Resonance-splitting and enhanced notch depth in SOI ring resonators with mutual mode coupling显示文摘 | Zhang Z Y Dainese M Wosinski L Qiu M | | 0，，07： | 1 |
| 7 | Reduction ascending aortoplasty: midterm follow-up and predictors of redilatation显示文摘 | Polvani G Barili F Dainese L | 2006 | Ann Thorac Surg2006，82，2： | 1 |
| 8 | FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer显示文摘AIM To evaluate the efficacy and safety of the modified FOLFIRI3-aflibercept as second-line therapy in patients with metastatic colorectal cancer.METHODS This is a retrospective multicenter cohort, evaluating the efficacy and safety of the association of aflibercept with FOLFIRI3(day 1: aflibercept 4 mg/kg, folinic acid 400 mg/m^2, irinotecan 90 mg/m^2, 5-fluorouracil infusion 2400 mg/m^2 per 46 h; day 3: irinotecan 90 mg/m^2) in patients with previously treated metastatic colorectal cancer. The primary endpoint was overall response rate(ORR). Secondary endpoints were disease control rate(DCR), progression-free survival(PFS), overall survival(OS), and safety.RESULTS Among 74 patients treated in four French centers, nine were excluded due to prior use of aflibercept(n = 3), more than one prior treatment line in irinotecanna?ve patients(n = 3), and inadequate liver function(n = 3). In the 'irinotecan-na?ve' patients(n = 30), ORR was 43.3% and DCR was 76.7%. Median PFS and OS were 11.3 mo(95%CI: 6.1-29.0) and 17.0 mo(95%CI: 13.0-17.3), respectively. The most common(> 5%) grade 3-4 adverse events were diarrhea(37.9%), neutropenia(14.3%), stomatitis and anemia(10.4%), and hypertension(6.7%). In the 'pre-exposed irinotecan' patients(n = 35), 20(57.1%) received ≥ 2 prior lines of treatment. ORR was 34.3% and DCR was 60.0%. Median PFS and OS were 5.7 mo(95%CI: 3.9-10.4) and 14.3 mo(95%CI: 12.8-19.5), respectively.CONCLUSION Minimally modified FOLFIRI has improvement dramatically the FOLFIRI3-aflibercept efficacy, whatever prior use of irinotecan. A prospective randomized trial is warranted to compare FOLFIRI-aflibercept to FOLFIRI3-aflibercept. | CANDice Carola Fran?ois Ghiringhelli Stefano Kim Thierry ANDré Juliette Barlet Le?la Bengrine-Lefevre Hélène Marijon Marie-Line Garcia-Larnicol Christophe Borg Linda Dainese Nils Steuer Hubert Richa Magdalena Benetkiewicz Annette K Larsen Aimery de Gramont Benoist Chibaudel | 2018 | World Journal of Clinical Oncology2018，9，5： | 1 |
| 9 | Resonance-splitting and enhanced notch depth in SOI ring resonators with mutual mode coupling显示文摘 | Zhang Z Y Dainese M Wosinski L | 2008 | Optics Express2008，16，7： | 1 |
| 10 | Resonance splitting and enhanced notch depth in SOI ring resonators with mutual mode coupling显示文摘 | Z Y Zhang M Dainese L Wosinski | 2008 | Opt Express2008，16，7： | 1 |
| 11 | Performance of a Two-pump Fiber Optic Parametric Amplifier in a 10Gb/s 64 Channel Dense Wavelength Division Multiplexing System显示文摘 | Chavez Boggio J M Dainese P Fragnito H L | 2003 | Opt Commun2003，218，： | 1 |
| 12 | Vertebroplasty:only small cement volumes are required to normalize stress distributions on the vertebral bodies显示文摘 | Luo J Daines L Charalambous A | | 0，，： | 1 |
| 13 | Reduction ascending aortoplast y: midterm follow-up and predictors of redilatation显示文摘 | Polvani G Barili F Dainese L | 2006 | Ann Thorac Surg2006，82，2： | 1 |
| 14 | Reduction ascending aortoplasty:midterm follow-up and predictors of redilatation显示文摘 | Polvani G>Barili F Dainese L | 2006 | Ann ThoracSurg2006，82，2： | 1 |
| 15 | On - and off - pump coronary surgery and perioperative myocardial infarction: an issue between incomplete and extensive revascularization显示文摘 | Alamanni F Dainese L Naliato M | 2008 | Eur J Cardiovasc Surg2008，34，1： | 1 |
| 16 | Cardiopulmonary bypass and oxyen consumption: oxygen delivery and hemodynamics显示文摘 | Parolari A Alamanni F Gherli T Bertera A Dainese L Costa C | 1999 | Ann Thorac Surg1999，67，： | 1 |
| 17 | Human or animal homograft:could they have a future as a biological scaffold for engineered heart valves显示文摘 | Dainese L Biglioli P | | 0，，： | 1 |
| 18 | Heart valve engineering:decel ularized aortic homograft seeded with human cardiac stromal cel s显示文摘 | Dainese L Guarino A Burba I | | 0，，01： | 1 |
| 19 | Compact arrayedwaveguide grating demuhiplexers based on amorphous silicon nanowires 显示文摘 | LIU L DAI D DAINESE M | 2006 | OSA Integrated Photonics Re- search and Applications/Nanophotonics2006，4，5： | 1 |
| 20 | Preoperative assessment of the radial artery for coronary arterybypass grafting:is the clinical Allen test adequate?显示文摘 | Agrifoglio M Dainese L Pasotti S | 2005 | Ann Thorac Surg2005，79，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员